Navigation Links
Pfizer Hemophilia presents new data at the World Federation of Hemophilia 2010 Congress

BUENOS AIRES, ARGENTINA, July 9 Pfizer Inc, the world's leading biopharmaceutical company, today announced that the results of a number of hemophilia studies will be presented at the World Federation of Hemophilia (WFH) 2010 Congress taking place July 10-14, 2010, in Buenos Aires, Argentina. Key research includes a pre-clinical evaluation of recombinant factor Xa as a potential new approach to restoring hemostasis, as well as a study assessing the potential for an engineered recombinant factor VIIa molecule to improve therapeutic outcomes in mouse models of hemophilia. These presentations follow Pfizer's recent announcement about the creation of a new research unit focused on rare diseases, including hemophilia.

"We are very excited to present these data, which highlights the strength of our pipeline and our enduring commitment to provide recombinant products for the hemophilia community," says Brenda Cooperstone, M.D., vice president of clinical development and medical affairs for the Specialty Care Business Unit at Pfizer. "Our investigation of novel therapies for hemophilia treatment remains ongoing and we will continue to work closely with our partnersincluding the World Federation of Hemophiliato help improve hemophilia care worldwide."

Early Research with Factor Xa and VIIa

Pfizer will present the results of a pre-clinical study in mice indicating that recombinant factor Xa therapy may provide a unique way to bypass deficiencies in the intrinsic pathway. Additional results from a preclinical study in mice suggest that a recombinant factor VIIa molecule with increased activity and duration of action may have the potential to improve inhibitor outcomes.

Additional Hemophilia Research from Pfizer at WFH

  • New model of antibody-induced hemophilia A for the assessment of bypass therapies
  • An electronic documentation system in Haemophilia provides otherwise unavailable feedback for continuous quality control first results from the Haemoassist system
  • A prospective registry of European hemophilia B patients receiving BeneFIX (nonacog alfa, recombinant human factor IX) for usual use
  • Two-year interim results of a non-interventional trial to assess the safety and efficacy of treatment with recombinant factor IX
  • Safety and efficacy of B-domain-deleted recombinant FVIII final results of a 10 year pharmacovigilance study

Pfizer's Ongoing Commitment to the WFH and the Hemophilia Community

Pfizer will make a contribution to WFH at the meeting in support of the Twinning Program, which aims to increase the level of diagnosis and care for people with hemophilia by pairing emerging treatment centers and patient organizations with more established centers and organizations around the world. Wyeth, now part of Pfizer, has acted as the exclusive corporate sponsor of the world-renowned program since 2001, which currently has 32 Twinning partnerships worldwide. Historically, there have been 149 Twinnings. Pfizer will also host the annual reception for the Twinning Program.


Contact: Gwen Fisher
Edelman Public Relations

Related medicine news :

1. Pfizer joins open-access medicinal chemistry public-private collaboration
2. VIDEO from Medialink and National Fibromyalgia Association and Pfizer Inc.: The Science Behind Fibromyalgia
3. Sigma-Aldrich Reaches Agreement to Sell Pfizers Bioactive Small Molecule Compounds
4. Arizona Myeloma Network presents Special Award to TGen president
5. Presents Aesthetic Diamond Jewelry and Diamond Watches at Wholesale Prices
6. Morehead Presents Webinar on “Managing the Paradox of Employee Alignment and Engagement”
7. RockWest Technology Group Presents Campus Contactless Card Technology at NACCU
8. NextAid Presents BIDS BUILD HOPE Online Auction to Benefit Projects on the Ground in Africa on World AIDS Orphans Day
9. Morehead Presents Webinar on “Creating a High-Performing RN Workforce”
10. Presents: Facebook Diamond Giveaway 2010
11. Aderans Research Presents at SID (Society of Investigative Dermatology)
Post Your Comments:
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, a ... can give their videos a whole new perspective by using the title layers ... Film Studios. , ProSlice Levels contains over 30 Different presets to choose from. ...
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica ... Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs ... Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, ...
(Date:6/25/2016)... ... 25, 2016 , ... Dr. Calvin Johnson has dedicated his ... implemented orthobiologic procedures as a method for treating his patients. The procedure is ... to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to help ...
(Date:6/24/2016)... ... , ... June 19, 2016 is World Sickle Cell Observance Day. In an ... of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a ... Cell Disease (SCD) is a disorder of the red blood cells, which can cause ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San ... Society and the Road To Recovery® program to drive cancer patients to and from ... adults to ensure the highest quality of life and ongoing independence. Getting to ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 2016 Research and Markets has ... by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), ... Parenteral) - Global Forecast to 2021" report to ... The global pharmaceutical excipients market is projected to reach ... 6.1% in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
(Date:6/23/2016)... PARK RIDGE, Ill. and INDIANAPOLIS ... caliber of students receiving a Lilly Diabetes Tomorrow,s Leaders ... hands. The 2016 scholarship winners, announced today online at ... refused to let type 1 diabetes stand in the ... Lilly Diabetes has supported the Foundation,s scholarship program since ...
Breaking Medicine Technology: